Sotera Health（SHC）株式概要
ソテラ・ヘルス・カンパニーは、米国、カナダ、ヨーロッパ、そして国際的に、ヘルスケア産業向けに滅菌ソリューション、ラボ検査、アドバイザリー・サービスを提供している。 詳細
SHC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Sotera Health Company 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$18.89 |
| 52週高値 | US$19.85 |
| 52週安値 | US$13.09 |
| ベータ | 1.78 |
| 1ヶ月の変化 | 6.42% |
| 3ヶ月変化 | 23.06% |
| 1年変化 | 20.01% |
| 3年間の変化 | 16.46% |
| 5年間の変化 | -17.51% |
| IPOからの変化 | -24.74% |
最新ニュース
ナラティブ更新 • Aug 07
SHC: Raised Outlook And Margin Assumptions Will Support Steady Future Returns
Analysts have raised their price target on Sotera Health from $16.00 to about $18.64, citing updated assumptions for fair value, discount rate, revenue growth, profit margins, and future P/E levels. What’s in the News for Sotera Health Sotera Health reported strong second quarter and first half 2026 results, with high single digit growth across its business units.Seeking Alpha • Jul 24
Sotera Health: Why We Plan To Own This For Many Years
Summary Sotera's Sterigenics business boasts 50% EBITDA margins, mission-critical regulated services, and cobalt-60 production that is nearly impossible to replicate. At their November 2024 Investor Day, management outlined a 2025-2027 plan targeting 5%-7% organic revenue growth and 5%-8% adjusted EBITDA growth, with at least 50bps of EBITDA margin expansion annually. Shader comes from Viant Medical, where he served as CEO since 2019, and holds a Stanford MBA. Once a medical device is validated for sterilization at a specific facility, changing that facility requires extensive regulatory work, testing, and approval. If the EPA finalizes the strict 2024 rule, Sotera's capital spend is justified, and competitors without the scale to absorb compliance costs will exit. Read the full article on Seeking AlphaRecent updates
ナラティブ更新 • Aug 07
SHC: Raised Outlook And Margin Assumptions Will Support Steady Future Returns
Analysts have raised their price target on Sotera Health from $16.00 to about $18.64, citing updated assumptions for fair value, discount rate, revenue growth, profit margins, and future P/E levels. What’s in the News for Sotera Health Sotera Health reported strong second quarter and first half 2026 results, with high single digit growth across its business units.Seeking Alpha • Jul 24
Sotera Health: Why We Plan To Own This For Many Years
Summary Sotera's Sterigenics business boasts 50% EBITDA margins, mission-critical regulated services, and cobalt-60 production that is nearly impossible to replicate. At their November 2024 Investor Day, management outlined a 2025-2027 plan targeting 5%-7% organic revenue growth and 5%-8% adjusted EBITDA growth, with at least 50bps of EBITDA margin expansion annually. Shader comes from Viant Medical, where he served as CEO since 2019, and holds a Stanford MBA. Once a medical device is validated for sterilization at a specific facility, changing that facility requires extensive regulatory work, testing, and approval. If the EPA finalizes the strict 2024 rule, Sotera's capital spend is justified, and competitors without the scale to absorb compliance costs will exit. Read the full article on Seeking Alpha
ナラティブ更新 • Jun 25
SHC: Equity Raise And 2026 Earnings Guidance Will Drive Future Upside
The analyst price target for Sotera Health has been nudged higher from $20.13 to about $20.22, reflecting analysts' updated modeling around fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What’s in the News for Sotera Health Sotera Health filed a follow on equity offering of 31,838,253 shares of common stock, classified as a follow on equity offering event.ナラティブ更新 • Jun 04
SHC: Equity Raise And Higher Guidance Are Expected To Drive Upside
Analysts have maintained their $20.13 price target for Sotera Health, citing only small adjustments in assumptions for discount rate, revenue growth, profit margin and future P/E multiples as the basis for keeping their view steady. What's in the News Sotera Health reported Q1 revenues of $280 million, a 10% year on year increase that came in 3.6% above analyst expectations, alongside growth in adjusted EBITDA and margin expansion, according to recent earnings coverage.分析記事 • May 13
Sotera Health's (NASDAQ:SHC) Performance Is Even Better Than Its Earnings Suggest
Sotera Health Company ( NASDAQ:SHC ) just reported healthy earnings but the stock price didn't move much. Investors are...ナラティブ更新 • May 12
SHC: Equity Raise And Reaffirmed 2026 Guidance Will Support Upside
Analysts have trimmed their price target on Sotera Health slightly from $20.50 to $20.13, citing updated assumptions for long term revenue growth, profit margins, and future P/E multiples. What's in the News Sotera Health plans a CEO transition, with Alton Shader set to become CEO and join the board on May 26, 2026.ナラティブ更新 • Apr 27
SHC: Follow On Equity Raise And 2026 Guidance Will Support Upside
Analysts now see a slightly lower price target for Sotera Health, trimming it from $20.75 to $20.50 as small adjustments to fair value, discount rate, revenue growth, profit margin and forward P/E estimates feed into their updated view. What's in the News Sotera Health completed a follow-on equity offering of 25,000,000 common shares, raising about US$381.75m at a price of US$15.27 per share (Key Developments).ナラティブ更新 • Apr 10
SHC: Equity Raise And 2026 Revenue Guidance Will Support Future Upside Potential
Analysts have maintained their $20.75 price target on Sotera Health, with only slight model adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions underpinning the updated view. What's in the News Sotera Health completed a follow on equity offering of 25,000,000 common shares, raising about $381.75 million at a price of $15.27 per share (company filing).ナラティブ更新 • Mar 27
SHC: Equity Raise And 2026 Guidance Will Support Future Upside Potential
Analysts are maintaining a price target of $20.75 for Sotera Health, with only modest tweaks to assumptions such as discount rate, long term revenue growth, profit margin and future P/E multiples, supporting an unchanged valuation view. What's in the News Sotera Health completed a follow on equity offering of 25,000,000 shares of common stock, raising approximately $381.75 million at a price of about $15.27 per share (company filing).ナラティブ更新 • Mar 10
SHC: Organic Investment And Margin Expansion Will Support Future Upside Potential
Analysts have raised their price target on Sotera Health to $20.75 from $20.44, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that reflect refreshed views on the company’s risk profile and earnings power. What's in the News Sotera Health filed a follow on equity offering of 25,000,000 shares of common stock, and later completed the offering for proceeds of US$381.75m at a price of US$15.27 per share, indicating recent access to equity capital markets.ナラティブ更新 • Feb 24
SHC: Organic Investment And Deleveraging Will Support Future Upside Potential
Analysts have kept their Sotera Health price target effectively unchanged at about $20.44, reflecting minimal updates to assumptions around the discount rate, long term revenue growth, profit margins, and future P/E expectations. What's in the News Sotera Health signaled that its primary use of capital remains focused on organic growth, with management highlighting continued investment to strengthen existing businesses.ナラティブ更新 • Feb 10
SHC: Organic Capital Deployment Will Support Deleveraging And Undervalued Upside
Analysts have maintained their price target for Sotera Health at approximately US$20.44, making only minor adjustments to inputs such as the discount rate, revenue growth, profit margin, and future P/E used in their valuation models. What's in the News Sotera Health signaled it will continue to focus its capital on organic growth initiatives, with CEO Michael Petras highlighting this as the primary use of funds during the JPMorgan Healthcare Conference (Key Developments).ナラティブ更新 • Jan 26
SHC: Equity Offering And Capital Allocation Priorities Will Guide Balanced Outlook
Analysts have modestly adjusted their price expectations for Sotera Health, with the updated target now at approximately US$20.44. This reflects small tweaks to assumptions such as the discount rate, long-term revenue growth, profit margin and future P/E.
新しいナラティブ • Jan 24
Bullish View Expects Sterilization Demand And Cobalt 60 Stability To Support Long-Term Upside
Catalysts About Sotera Health Sotera Health provides sterilization services and lab testing that support global health care and medical products. What are the underlying business or industry changes driving this perspective?ナラティブ更新 • Jan 12
SHC: Follow-On Equity Offering And Lock-Up Terms Will Shape Balanced Outlook
Analysts have lifted their price target for Sotera Health to US$20.44 from US$18.93, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E expectations. What's in the News Sotera Health completed a follow on equity offering of 30,000,000 common shares, raising about US$471 million at a price of US$15.70 per share with a US$0.049 discount per share (Key Developments).分析記事 • Jan 09
Is Sotera Health Company (NASDAQ:SHC) Potentially Undervalued?
Sotera Health Company ( NASDAQ:SHC ), is not the largest company out there, but it led the NASDAQGS gainers with a...ナラティブ更新 • Dec 15
SHC: Follow-On Equity Offering Will Drive Bullish Share Performance Next Year
Narrative Update Analysts have modestly raised their price target on Sotera Health, citing fine tuned assumptions around discount rates, revenue growth, margins, and future earnings multiples as justification for a slightly higher implied fair value near $18.93 per share. What's in the News Sotera Health has completed a follow-on equity offering of approximately $471 million, issuing 30 million shares of common stock at about $15.70 per share (Key Developments) The company has filed a separate follow-on equity offering totaling roughly $480.3 million for 30 million shares of common stock, with an indicated price of about $16.01 per share (Key Developments) Executive officers, directors and selling stockholders have agreed to a lock-up on 284,093,929 common shares, restricting most sales and hedging activity from November 6, 2025 to December 7, 2025 (Key Developments) Certain restricted stock units held by insiders are also subject to the same 31-day lock-up period ending December 7, 2025 (Key Developments) Options held by executives, directors and selling stockholders will likewise be restricted during the November 6 to December 7, 2025 lock-up window (Key Developments) Valuation Changes Fair Value: Unchanged at an implied price of approximately $18.93 per share.ナラティブ更新 • Nov 30
SHC: Follow-On Offering And Lock-Up Expiration Will Shape Shares Next Year
Analysts have maintained their price target for Sotera Health at $18.93, citing consistent expectations for growth and profitability metrics along with minor adjustments to underlying discount rates and projected price-to-earnings ratios. What's in the News Sotera Health Company has completed a Follow-on Equity Offering valued at $471 million, issuing 30 million shares of common stock at $15.70 each (Key Developments).ナラティブ更新 • Nov 16
SHC: Improved Profit Margins Will Drive Future Share Price Upside
Analysts have raised their price target for Sotera Health from $17.00 to $18.93 per share. They cite an improved profit margin outlook despite slightly lower revenue growth projections.分析記事 • Nov 11
Sotera Health's (NASDAQ:SHC) Conservative Accounting Might Explain Soft Earnings
The most recent earnings report from Sotera Health Company ( NASDAQ:SHC ) was disappointing for shareholders. However...分析記事 • Nov 07
Results: Sotera Health Company Beat Earnings Expectations And Analysts Now Have New Forecasts
Sotera Health Company ( NASDAQ:SHC ) investors will be delighted, with the company turning in some strong numbers with...ナラティブ更新 • Nov 01
SHC: Recent Equity Offerings And Lock-Up Expiry Will Shape Market Outlook
Narrative Update on Sotera Health Analysts have maintained their price target for Sotera Health at $17.00 per share. They cite unchanged growth expectations and financial metrics that support the previous valuation.ナラティブ更新 • Oct 17
Expanding Sterilization Capacity And EPA Compliance Will Unlock New Markets
Narrative Update: Sotera Health Analyst Price Target Adjustment Analysts have raised their price target for Sotera Health from $16.33 to $17.00 per share. This adjustment reflects a more optimistic outlook based on modest improvements in projected fair value and valuation metrics.ナラティブ更新 • Oct 03
Expanding Sterilization Capacity And EPA Compliance Will Unlock New Markets
Analysts have modestly raised their price target for Sotera Health from $16.00 to approximately $16.33. This reflects incremental updates in growth and valuation assumptions.ナラティブ更新 • Aug 10
Expanding Sterilization Capacity And EPA Compliance Will Unlock New Markets
Sotera Health's consensus price target has increased to $15.75 as analysts reacted positively to a significant rise in net profit margin and a substantial decline in forward P/E, indicating improved profitability and valuation. What's in the News Sotera Health raised full-year 2025 earnings guidance, increasing expected net revenue growth to 4.5%–6.0% from 4.0%–6.0% on a constant currency basis.株主還元
| SHC | US Life Sciences | US 市場 | |
|---|---|---|---|
| 7D | 0.2% | 0.2% | 0.6% |
| 1Y | 20.0% | 18.6% | 20.1% |
業界別リターン: SHC過去 1 年間で18.6 % の収益を上げたUS Life Sciences業界を上回りました。
リターン対市場: SHCは、過去 1 年間で20.1 % のリターンをもたらしたUSマーケットと一致しました。
価格変動
| SHC volatility | |
|---|---|
| SHC Average Weekly Movement | 4.3% |
| Life Sciences Industry Average Movement | 7.8% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: SHC 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: SHCの 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2015 | 3,000 | Alton Shader | soterahealth.com |
ソテラ・ヘルス・カンパニーは、米国、カナダ、欧州、および国際的なヘルスケア産業向けに滅菌ソリューション、ラボ検査、アドバイザリーサービスを提供している。同社は3つのセグメントで事業を展開：ステリジェニクス、ノルディオン、ネルソンラボ。Sterigenics部門は、医療機器、医薬品、食品安全、先端アプリケーション市場向けに、ガンマ線照射、エチレンオキサイド処理、電子ビーム照射技術を用いた端末滅菌・照射のアウトソーシングサービスを提供している。ノルディオン部門では、医療機器、製薬、食品安全、高機能材料産業、がん治療などの滅菌・照射工程で使用されるコバルト60を提供している。また、ガンマ線照射システムも提供している。ネルソンラボ部門は、医療機器および製薬業界向けに、微生物学的および分析化学的試験のアウトソーシングとアドバイザリーサービスを提供している。同社は以前Sotera Health Topco, Inc.として知られていたが、2020年10月にSotera Health Companyに社名変更した。ソテラ・ヘルス・カンパニーは2015年に法人化され、オハイオ州ブロードビューハイツに本社を置いている。
Sotera Health Company 基礎のまとめ
| SHC 基礎統計学 | |
|---|---|
| 時価総額 | US$5.39b |
| 収益（TTM） | US$163.48m |
| 売上高(TTM) | US$1.22b |
33.0x
PER（株価収益率4.4x
P/SレシオSHC は割高か？
公正価値と評価分析を参照収益と収入
| SHC 損益計算書（TTM） | |
|---|---|
| 収益 | US$1.22b |
| 売上原価 | US$547.66m |
| 売上総利益 | US$668.51m |
| その他の費用 | US$505.04m |
| 収益 | US$163.48m |
直近の収益報告
Jun 30, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 0.57 |
| グロス・マージン | 54.97% |
| 純利益率 | 13.44% |
| 有利子負債／自己資本比率 | 321.4% |
SHC の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/16 11:03 |
| 終値 | 2026/08/14 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Sotera Health Company 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14
| アナリスト | 機関 |
|---|---|
| Michael Polark | Baird |
| Luke Sergott | Barclays |
| Sean Dodge | BMO Capital Markets Equity Research |